Sky Labs Inc. Lists on KOSDAQ... "Beyond Cuffless Blood Pressure Monitors to a Medical Data Platform"

[Financial News] Sky Labs Inc. is listing on the KOSDAQ market on the 4th and is embarking on the global expansion of its cuffless blood pressure monitoring business. The company plans to broaden its business scope from blood pressure measuring devices to a platform company that encompasses multiple biosignals and medical data.
Sky Labs Inc. is a medical device company that produces biometric data based on its own hardware and artificial intelligence (AI) algorithms. Its flagship product is the ring-shaped cuffless blood pressure monitor 'CART BP pro'. It is designed to measure blood pressure changes 24 hours a day, even during daily activities or sleep, without the need to wrap a cuff around the arm.
As of June 2026, CART BP pro has been introduced to approximately 2,000 hospitals and clinics nationwide, including the top five hospitals in Korea. In the year following the product launch, the number of prescriptions for 24-hour ambulatory blood pressure monitoring (E6547) in Korea also increased by 52.7% compared with before the launch. Of these, CART BP pro accounted for 52.4%.
The company is also accelerating its expansion into overseas markets. Following the acquisition of European CE-MDR approval and UK MHRA registration, Sky Labs Inc. recently signed a supply contract with IEM GmbH, a European company specializing in 24-hour ambulatory blood pressure monitoring (ABPM). Based on this, the company plans to target hospital and clinic markets in major European countries, including the UK and Germany.
The proportion of overseas sales is also increasing. In the first half of this year, overseas sales accounted for 52% of Sky Labs Inc.'s total revenue. While expanding into the European and Japanese markets by leveraging partnerships with global companies such as OMRON Healthcare and Otsuka Pharmaceutical Co., Ltd., the company is also pursuing entry into the U.S. market through approval from the U.S. Food and Drug Administration (FDA).
Sky Labs Inc. plans to expand its product line, which is currently focused on blood pressure measurement, into the multi-biosignal domain. The company intends to broaden its scope into the data business, which can be utilized for pharmaceutical companies' clinical trials and medical AI, through its proprietary medical data platform, 'CART NET'.
Lee Byung-hwan, CEO of Sky Labs Inc., said, "Following the listing, we will accelerate our entry into the global market and leap forward as a global medical data production platform company based on accumulated medical data."

[email protected] Jeong Sang-hee Reporter